Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545813 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL352379 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL473498 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL2619233 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL29414359 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL421235 | 0.75 | DYRK1A (0.52) | GRM4 | |
| SCHEMBL11874314 | 0.75 | GRM4 (0.39) | GRM4MAPK14 | |
| SCHEMBL30132904 | 0.75 | DYRK1A (0.52) | GRM4 | |
| SCHEMBL15935281 | 0.71 | GRM4 (0.37) | GRM4 | |
| SCHEMBL10223032 | 0.71 | GRM4 (0.37) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238570-A1 | CDK2 INHIBITOR PYRAZOLOPYRIMIDINE COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240262831-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-08-08 | — | — | US | disclosed |
| CN-117479933-A | Compounds for the treatment of neurodegenerative disorders, degenerative disorders and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4262792-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4115882-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022133303-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-3302486-B1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| EP-1208102-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES | Neurocrine Biosciences, Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001092264-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| US-20010044531-A1 | Nucleic acid labeling compounds | AFFYMETRIX, INC. | 2001-11-22 | — | — | US | disclosed |
| US-20010018514-A1 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX, INC. | 2001-08-30 | — | — | US | disclosed |
| EP-1124838-A2 | NUCLEIC ACID LABELING COMPOUNDS | Affymetrix, Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001010868-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000006771-A2 | NUCLEIC ACID LABELING COMPOUNDS | AFFYMETRIX, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0095289-B1 | IMIDAZO(1,2-C)PYRAZOLO(3,4-E)PYRIMIDINES AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4469868-A | ANTIPSYCHOTIC ANGENTS | WARNER-LAMBERT COMPANY (US) | 1984-09-04 | — | — | US | disclosed |
| EP-0095289-A2 | Imidazo(1,2-c)pyrazolo(3,4-e)pyrimidines and their production | WARNER-LAMBERT COMPANY (US) | 1983-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | GRM4 2876/4885MAPK14 4367/4885 |
| US-20010044531-A1 | Nucleic acid labeling compounds | RNGTT, DUT, FBL | GRM4 3991/4885MAPK14 3449/4885 |
| US-20010018514-A1 | NUCLEIC ACID LABELING COMPOUNDS | RNGTT, DUT, FBL | GRM4 3991/4885MAPK14 3449/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | GRM4 2876/4885MAPK14 4367/4885 |
| US-20240262831-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | GRM4 871/4885MAPK14 2241/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | GRM4 2876/4885MAPK14 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.